Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in Haemodialysis Patients

Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in Haemodialysis

• How dyslipidemia common among Diabetic and non- Diabetic Haemodialysis patients.
• How differ dyslipidemia types among Diabetic and non- Diabetic in Haemodialysis patients. (Qualitative difference).

Study Overview

• Status: Not yet recruiting
• Conditions: Dyslipidemias
• Intervention / Treatment: Procedure: haemodialysis

Detailed Description

Diabetes mellitus (DM) is a metabolic disease , a consequence of defects in insulin action, secretion, or both, and there are complications associated with it, such as nephropathy, retinopathy, neuropathy, cardiovascular complications ,cerebrovascular and peripheral arterial disease. Diabetic nephropathy, which occurs in about one third of type 2 diabetic patients, is the most common factor leading to end-stage renal disease (ESRD) . A very common metabolic abnormality associated with diabetes is dyslipidemia, which is characterized by a spectrum of quantitative and qualitative changes in lipids and lipoproteinsSeveral previous studies have pursued linking blood glucose levels to serum lipid activities. The etiology of dyslipidemia appears to be centered on the increased large TAG-rich very low-density lipoprotein-cholesterol (VLDL-C) and its impaired clearance. American diabetic association (ADA) defines dyslipidemia as hypercholesterolemia ≥200 mg/dl of serum total cholesterol, hypertriglyceridemia ≥150 mg/dl of serum triglyceride, reduced high density lipoprotein cholesterol (HDL-C) <40 mg/dl for men and <50 mg/dl for women, elevated low density lipoprotein cholesterol (LDL-C) ≥70 mg/dl and high TC to HDL-C ratio of ≥4.5. Normal plasma lipids and lipoprotein metabolism is critical for cellular cholesterol homeostasis and protection against atherosclerosis, renal disease and other complication . A study found that people with high blood pressure and overweight or obesity have a higher risk of developing dyslipidemia ,Early detection and effective control of blood lipid levels can reduce the morbidity and mortality of CVD in patients with DM. Therefore, it is important to determine the factors associated with dyslipidemia.

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: dina A. Abudeif, doctor; Phone Number: +201141210144; Email: dinaaliabudeif7@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

haemodialysis patients for more than six months, and is with diabetes related to affect prevalance of dyslipidemia among these patients

Description

Inclusion Criteria:

• Patients aged between 18 and 60 years.
• Patients undergoing regular conventional Haemodialysis for more than 6 months

Exclusion Criteria:

• Peritoneal Dialysis
• Haemodiafilteration
• Acute Kidney Injury
• Nephrotic syndrome
• Hypothyroidism
• Familial hypertriglyceridemia.
• Acute pancreatitis
• Connective tissue disease.
• Decompensated liver disease
• Active malignancy.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
diabetic dialysis patients; fifty diabetic patients on regular haemodialysis more than 6 months	Procedure: haemodialysis; process of filtering the blood of a person whose kidneys are not working normally from uremic toxins
Non-diabetic dialysis patients; fifty Non-diabetic patients on regular haemodialysis more than 6 months	Procedure: haemodialysis; process of filtering the blood of a person whose kidneys are not working normally from uremic toxins

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
dyslipidemia prevalence among Diabetic versus non- Diabetic Haemodialysis patients	haemodialysis patients for more than six months, and is with diabetes related to affect prevalance of dyslipidemia among these patients	baseline

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Study Director: Salwa S. Elgendi, professor, Assiut University; Study Director: Essam M. Abdel-Aziz, doctor, Assiut University

Publications and helpful links

General Publications

• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88-98. doi: 10.1038/nrendo.2017.151. Epub 2017 Dec 8.
• Biadgo B, Abebe SM, Baynes HW, Yesuf M, Alemu A, Abebe M. Correlation between Serum Lipid Profile with Anthropometric and Clinical Variables in Patients with Type 2 Diabetes Mellitus. Ethiop J Health Sci. 2017 May;27(3):215-226. doi: 10.4314/ejhs.v27i3.3.
• Ariyanti R, Besral B. Dyslipidemia Associated with Hypertension Increases the Risks for Coronary Heart Disease: A Case-Control Study in Harapan Kita Hospital, National Cardiovascular Center, Jakarta. J Lipids. 2019 Apr 30;2019:2517013. doi: 10.1155/2019/2517013. eCollection 2019.
• Hasan YK, Alsultan M, Anan MT, Hassn Q, Basha K. The prevalence of dyslipidemia in patients on hemodialysis: a cross-sectional study from Syria. Ann Med Surg (Lond). 2023 Jun 5;85(8):3838-3844. doi: 10.1097/MS9.0000000000000931. eCollection 2023 Aug.

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2024
• Primary Completion (Estimated): June 1, 2025
• Study Completion (Estimated): December 30, 2025

Study Registration Dates

• First Submitted: May 2, 2024
• First Submitted That Met QC Criteria: May 2, 2024
• First Posted (Actual): May 6, 2024

Study Record Updates

• Last Update Posted (Actual): May 6, 2024
• Last Update Submitted That Met QC Criteria: May 2, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Keywords: haemodialysis diabetes mellitus
• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Dyslipidemias
• Other Study ID Numbers: Dyslipidemia haemodialysis

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No